Women between the ages of 50 and 64 use medications the most. Nearly 12% of people in the United States have taken GLP-1 medications for weight loss, with usage especially common among women ages 50 ...

The clinical-stage biopharmaceutical firm, Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, develops novel ...

U.S. District Judge Karen Marston, of the Eastern District of Pennsylvania, allowed some misrepresentation claims to go ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

NAION is a rare form of vision loss that’s been linked to semaglutide, the active ingredient in Wegovy and Ozempic.

According to NPR, doctors and patients alike have noted the drug has appeared to reduce some people's cravings for booze, ...

GLP-1 drugs suppress appetite and have been shown to reduce calorie intake by up to 800 calories per person per day. GLP-1 ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.

Using GLP-1 drugs for weight loss is considered safe but can come with a loss of lean muscle mass. It’s crucial to do ...